To facilitate the integration of the chemogenomic tool and of the Minimal Residual Disease (MRD) detection kit in the health care system, we are conducting:

  • A study to highlight the strengths and weaknesses of the Canadian federal and provincial regulatory approval models and to outline the criteria for the legal and ethical recognition of novel technologies
  • Recommendations regarding the obligation of clinical lab directors to inform treating physicians of clinically valuable information resulting from AML research
  • A cost effectiveness study on AML diagnostic and prognostic tests and therapy